These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38316483)

  • 1. Impact of semaglutide and dulaglutide shortages on Pharmaceutical Benefits Scheme prescriptions supplied for type 2 diabetes treatment.
    Phakey S; Shen A
    Aust J Gen Pract; 2024; 53(1-2):57-61. PubMed ID: 38316483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
    Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy.
    Boye KS; Matza LS; Stewart KD; Jordan J; Biricolti G; Del Santo S; Perez-Nieves M; Federici MO; Gentilella R; Losi S; Norrbacka K
    J Med Econ; 2019 Aug; 22(8):806-813. PubMed ID: 31010349
    [No Abstract]   [Full Text] [Related]  

  • 5. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
    Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF
    Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
    Mody R; Yu M; Nepal B; Konig M; Grabner M
    Diabetes Obes Metab; 2021 Jan; 23(1):106-115. PubMed ID: 32945083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.
    Pratley RE; Catarig AM; Lingvay I; Viljoen A; Paine A; Lawson J; Chubb B; Gorst-Rasmussen A; Miresashvili N
    Diabetes Obes Metab; 2021 Nov; 23(11):2513-2520. PubMed ID: 34286894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.
    Mody R; Manjelievskaia J; Marchlewicz EH; Malik RE; Zimmerman NM; Irwin DE; Yu M
    Clin Ther; 2022 Apr; 44(4):537-554. PubMed ID: 35264311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
    Kimura T; Kubo M; Takahashi K; Wamata R; Iwamoto Y; Iwamoto H; Katakura Y; Sanada J; Fushimi Y; Shimoda M; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Res; 2024; 2024():5880589. PubMed ID: 38223524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.
    Powell J; Taylor J
    Clin Ther; 2024 Mar; 46(3):289-292. PubMed ID: 38310052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
    Matza LS; Boye KS; Stewart KD; Coyne KS; Wullenweber PK; Cutts KN; Jordan JB; Wang Q; Yu M; Currie BM; Malley KG; Ishak KJ; Hietpas RT; García-Pérez LE
    Diabetes Obes Metab; 2020 Mar; 22(3):355-364. PubMed ID: 31646727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
    Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
    Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
    Kimura T; Katakura Y; Shimoda M; Kawasaki F; Yamabe M; Tatsumi F; Matsuki M; Iwamoto Y; Anno T; Fushimi Y; Kamei S; Kimura Y; Nakanishi S; Mune T; Kaku K; Kaneto H;
    Diabetes Obes Metab; 2023 Dec; 25(12):3632-3647. PubMed ID: 37646192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
    Ericsson Å; Fridhammar A
    J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636
    [No Abstract]   [Full Text] [Related]  

  • 16. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
    Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T
    Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.
    Tham LS; Pantalone KM; Dungan K; Munir K; Tang CC; Konig M; Kwan AYM
    Diabetes Obes Metab; 2022 Feb; 24(2):302-311. PubMed ID: 34697882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis.
    Igarashi A; Hunt B; Wilkinson L; Langer J; Pollock RF
    Adv Ther; 2020 Oct; 37(10):4446-4457. PubMed ID: 32870471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care.
    von Arx LB; Rachman J; Webb J; Casey C; Patel A; Diomatari C; Wood R; Idris I
    Diabetes Obes Metab; 2023 May; 25(5):1331-1340. PubMed ID: 36692268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression.
    Lingvay I; Bauer R; Baker-Knight J; Lawson J; Pratley R
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1461-1469. PubMed ID: 34922383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.